Viemed Q2 Revenue Hits Record $78.1M, Raises Low End of 2026 Guidance
VMD sits 85% above its 52-week low of $5.93.
Summary
Viemed posted Q2 revenue of $78.1M, up 24% YoY and in line with consensus, driven by record ventilator patient census and strong PAP therapy volume. Adjusted EBITDA fell 4% due to a prior-year non-recurring gain. The company tightened its 2026 revenue guidance range upward to $314M-$320M from $312M-$320M, while trimming the Adjusted EBITDA outlook to $64M-$68M from $65M-$69M. Capex guidance was also lowered slightly. The quarter included $5.1M in share repurchases. The mixed guidance revision—higher revenue floor but lower EBITDA ceiling—keeps the overall tone neutral, though the revenue momentum and buyback activity are modest positives.
At the time of this announcement, VMD was trading at $11.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $448.2M. The 52-week trading range was $5.93 to $12.61. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.